Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2016—The Clinical and Laboratory Standards Institute has published a new document titled “Management of Critical- and Significant-Risk Results (GP47-Ed1).” This guideline provides current best practice recommendations for developing and implementing a policy and procedures for the identification, reporting, and management of critical- and significant-risk laboratory results.
February 2016—Illumina launched its MiniSeq Sequencing System and, during a presentation at the J.P. Morgan Healthcare Conference, Jan. 11–14 in San Francisco, introduced the Infinium XT and previewed Project Firefly, which will lead to the commercialization of a new semiconductor-based sequencing system.
February 2016—Primera Trio from Primera Technology is a small, lightweight, portable all-in-one printer. Designed for nurses and doctors to print on demand at hospitals and home care facilities, Primera Trio prints, copies, and scans in full color or black monochrome from a unit that weighs 2.6 pounds and is about the size of a hardcover book.
February 2016—Enzo Life Sciences now offers EQ Quencher Dyes—amine-reactive quencher dyes that can be used for fluorescence resonance energy transfer (FRET) applications.
February 2016—Hamilton Storage introduced RackWare HD138 and HD60 high-density SBS-footprint racks for microtube and cryovial storage. Designed for use with Hamilton’s BiOS, SAM, and Verso sample management and storage systems, RackWare increases storage capacity by increasing the number of tubes that can be placed in an SBS-footprint rack. The racks can also be used to maximize storage in manual freezers.
February 2016—MDxHealth announced that data demonstrating the clinical potential of its urine-based epigenetic bladder cancer test AssureMDx, to aid urologists in the management of patients presenting with hematuria, has been published in The Journal of Urology.
February 2016—Epic Sciences announced a collaboration with University of Pennsylvania’s Abramson Cancer Center on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells at a single cell resolution, that are predictive of response to personalized cancer therapeutics.
February 2016—ScyTek Laboratories announced the availability of Pan Melanoma Cocktail antibody. This cocktail includes Tyrosinase, MART-1, and HMB45 clones.
February 2016—Biocartis launched two products on its molecular diagnostics platform Idylla. The first offering, the Idylla ctBRAF Mutation Assay, uses blood plasma as a sample. The assay can potentially act as a substitute for tissue biopsy testing in melanoma and colorectal and lung cancers, as well as conditions such as hairy cell leukemia and histiocytosis. It has a turnaround time of approximately 90 minutes with less than one minute of hands-on time.
February 2016—Roche launched the Ventana HE 600 system, its latest fully automated hematoxylin and eosin tissue staining system designed to enhance patient and technician safety and produce exceptional staining quality.
